文献速递创伤与烧伤重症综合管理与镇静镇痛

α7烟碱型乙酰胆碱受体激动剂GTS-21促进C2C12肌核增生并与白细胞介素-6释放相关,改善烧伤小鼠生存

An ALPHA7 Nicotinic Acetylcholine Receptor Agonist (GTS-21) Promotes C2C12 Myonuclear Accretion in Association with Release of Interleukin-6 (IL-6) and Improves Survival in Burned Mice.
PubMed 文献 · Shock · 2017-01-01
一句话结论在烧伤小鼠中,GTS-21使野生型死亡率从75%降至0%,IL-6敲除小鼠死亡率从100%降至75%。

该研究在体外C2C12肌母细胞和肌管中测试GTS-21对IL-6释放的影响,并在烧伤野生型和IL-6敲除小鼠中测试GTS-21对生存的作用。GTS-21剂量依赖性增加肌母细胞和肌管IL-6水平,该效应可被α7AChR拮抗剂及Stat-3或Stat-5抑制剂减弱。GTS-21增加MyoD和Pax7蛋白表达、肌核增生及胰岛素诱导的Akt、GSK-3β和Glut4磷酸化。烧伤野生型小鼠75%死亡率经GTS-21降至0%,IL-6敲除小鼠100%死亡率降至75%。作者认为α7AChR激动剂可能具有治疗烧伤的潜在应用价值。

要点

  • 烧伤野生型小鼠死亡率75%经GTS-21降至0%,IL-6敲除烧伤小鼠死亡率100%经GTS-21降至75%。
  • GTS-21在0 μM、100 μM、200 μM浓度下剂量依赖性增加肌母细胞和肌管6 h和9 h的IL-6水平。
  • GTS-21诱导的肌管IL-6释放可被甲基牛扁亭碱(α7AChR拮抗剂)及Stat-3或Stat-5抑制剂减弱。
  • GTS-21增加肌管MyoD和Pax7蛋白表达、肌核增生及胰岛素诱导的Akt、GSK-3β和Glut4磷酸化。
  • 作者认为α7AChR激动剂可能具有治疗烧伤的潜在应用价值。

适用人群与场景

  • 体外实验:C2C12肌母细胞和7天分化肌管。
  • 体内实验:烧伤野生型小鼠和IL-6敲除小鼠。

处置流程与药物剂量

  • 体外:GTS-21在0 μM、100 μM、200 μM浓度下作用于肌母细胞和肌管,于6 h和9 h检测IL-6水平。
  • 体外:甲基牛扁亭碱(α7AChR拮抗剂)、Stat-3或Stat-5抑制剂用于减弱GTS-21诱导的肌管IL-6释放。
  • 体内:GTS-21用于烧伤野生型小鼠和IL-6敲除小鼠,观察死亡率及血糖变化。

研究设计与关键结果

  • 研究类型:体外细胞实验联合体内小鼠实验;样本量原文未报告;无中心数信息。
  • 体外:GTS-21剂量依赖性(0 μM、100 μM、200 μM)显著增加肌母细胞和肌管6 h和9 h的IL-6水平。
  • 体外:GTS-21诱导的肌管IL-6释放被甲基牛扁亭碱及Stat-3或Stat-5抑制剂减弱。
  • 体外:GTS-21增加肌管MyoD和Pax7蛋白表达、肌核增生及胰岛素诱导的Akt、GSK-3β和Glut4磷酸化。
  • 体内:接受GTS-21的烧伤IL-6敲除小鼠血糖水平较假烧伤IL-6敲除小鼠显著降低。
  • 体内:烧伤叠加于IL-6敲除小鼠导致100%死亡率,GTS-21使IL-6敲除小鼠死亡率降至75%。
  • 体内:烧伤野生型小鼠死亡率75%,GTS-21使其降至0%。

证据类型、等级与局限

  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为α7AChR激动剂在烧伤治疗中具有潜在应用价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

The role of interleukin-6 (IL-6) in physiological processes and disease is poorly understood. The hypothesis tested in this study was that selective alpha7 acetylcholine receptor (α7AChR) agonist, GTS-21, releases IL-6 in association with myonuclear accretion and enhances insulin signaling in muscle cells, and improves survival of burn injured (BI) mice. The in vitro effects of GTS-21 were determined in C2C12 myoblasts and 7-day differentiated myotubes (myotubes). The in vivo effects of GTS-21 were tested in BI wild-type (WT) and IL-6 knockout (IL6KO) mice. GTS-21 dose-dependently (0 μM, 100 μM, and 200 μM) significantly increased IL-6 levels in myoblasts and myotubes at 6 and 9 h. GTS-21-induced IL-6 release in myotubes was attenuated by methyllycaconitine (α7AChR antagonist), and by Stat-3 or Stat-5 inhibitors. GTS-21 increased MyoD and Pax7 protein expression, myonuclear accretion, and insulin-induced phosphorylation of Akt, GSK-3β, and Glut4 in myotubes. The glucose levels of burned IL6KO mice receiving GTS-21 decreased significantly compared with sham-burn IL6KO mice. Superimposition of BI on IL6KO mice caused 100% mortality; GTS-21 reduced mortality to 75% in the IL6KO mice. The 75% mortality in burned WT mice was reduced to 0% with GTS-21. The in vitro findings suggest that GTS-21-induced IL-6 release from muscle is mediated via α7AChRs upstream of Stat-3 and -5 pathways and is associated with myonuclear accretion, possibly via MyoD and Pax7 expression. GTS-21 in vivo improves survival in burned WT mice and IL6KO mice, suggesting a potential therapeutic application of α7AChR agonists in the treatment of BI.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Khan MAS, Khan MF, Kashiwagi S, et al. An ALPHA7 Nicotinic Acetylcholine Receptor Agonist (GTS-21) Promotes C2C12 Myonuclear Accretion in Association with Release of Interleukin-6 (IL-6) and Improves Survival in Burned Mice. Shock. 2017. PMID: 28282360. doi:10.1097/SHK.0000000000000849

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。